Profile data is unavailable for this security.
About the company
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
- Revenue in USD (TTM)160.40m
- Net income in USD-62.64m
- Incorporated2019
- Employees180.00
- LocationArcturus Therapeutics Holdings Inc10628 Science Center Dr Ste 250SAN DIEGO 92121-1132United StatesUSA
- Phone+1 (858) 900-2660
- Fax+1 (302) 636-5454
- Websitehttps://arcturusrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allogene Therapeutics Inc | 43.00k | -283.43m | 442.41m | 232.00 | -- | 0.9532 | -- | 10,288.56 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Taysha Gene Therapies Inc | 9.92m | -22.77m | 446.78m | 52.00 | -- | 5.03 | -- | 45.06 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Omeros Corp | 0.00 | -185.38m | 447.93m | 198.00 | -- | -- | -- | -- | -3.14 | -2.30 | 0.00 | -2.66 | 0.00 | -- | -- | 0.00 | -45.98 | -55.51 | -61.42 | -70.10 | -- | -- | -- | -- | -- | -6.07 | 1.59 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Aura Biosciences Inc | 0.00 | -83.22m | 447.94m | 88.00 | -- | 2.57 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -122.68m | 450.69m | 87.00 | -- | 2.27 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 452.37m | 100.00 | -- | 4.89 | -- | 5.35 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Regenxbio Inc | 84.33m | -238.81m | 454.82m | 344.00 | -- | 1.51 | -- | 5.39 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
OmniAB Inc | 20.41m | -63.02m | 454.93m | 106.00 | -- | 1.59 | -- | 22.29 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
MeiraGTx Holdings PLC | 13.93m | -88.18m | 456.93m | 389.00 | -- | 4.80 | -- | 32.80 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 457.69m | 150.00 | -- | 2.32 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 462.38m | 180.00 | -- | 1.77 | -- | 2.88 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Korro Bio Inc | 0.00 | -101.60m | 470.71m | 95.00 | -- | 2.63 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Celcuity Inc | 0.00 | -93.97m | 471.39m | 55.00 | -- | 3.16 | -- | -- | -2.61 | -2.61 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -45.24 | -37.32 | -49.93 | -39.16 | -- | -- | -- | -- | -- | -- | 0.393 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Terns Pharmaceuticals Inc | 0.00 | -88.07m | 481.92m | 66.00 | -- | 1.33 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Holder | Shares | % Held |
---|---|---|
Federated Global Investment Management Corp.as of 30 Sep 2024 | 4.69m | 17.36% |
Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 2.32m | 8.56% |
BlackRock Fund Advisorsas of 30 Sep 2024 | 2.16m | 7.98% |
ARK Investment Management LLCas of 30 Sep 2024 | 2.10m | 7.77% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 1.52m | 5.61% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.47m | 5.45% |
Woodline Partners LPas of 30 Sep 2024 | 779.96k | 2.88% |
Dimensional Fund Advisors LPas of 30 Sep 2024 | 741.36k | 2.74% |
Geode Capital Management LLCas of 30 Sep 2024 | 551.80k | 2.04% |
Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 442.98k | 1.64% |